Omniscient Neurotechnology raises $15M strategic from Stryker and initiates 500-patient Hopkins DBS study
Summary
Omniscient Neurotechnology announced simultaneous closure of a $15M strategic investment from Stryker Neurovascular and initiation of a 500-patient connectome-guided DBS outcomes study at Johns Hopkins. The dual announcement — major MedTech strategic investment plus landmark academic partnership — was described by CEO Michael Toth as a deliberate commercial and scientific credibility building strategy.
Why it matters
Executing a Stryker strategic investment and a Johns Hopkins partnership simultaneously is exceptional commercial strategy — the strategic validates technology, the academic partnership validates science. Both announcements together create a defensible moat that neither alone would produce.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial